Gyre Therapeutics (GYRE) announced that the first volunteer has been successfully dosed in a Phase 1 clinical trial evaluating F230, a novel endothelin A receptor antagonist, for the treatment of pulmonary arterial hypertension. F230, originally discovered by Eisai (ESAIY) and exclusively licensed by GNI Group Ltd. to Gyre, is a fully synthetic small molecule designed to selectively block the ETA receptor. By targeting this pathway, F230 is designed to reduce pulmonary vascular remodeling and lower pulmonary pressure, key contributors to PAH progression.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GYRE:
- Gyre Therapeutics Holds 2025 Annual Stockholders Meeting
- Gyre Therapeutics Announces Stock Offering Agreement
- Stocks slide as Trump threatens new tariffs against EU and Apple: Morning Buzz
- Catalyst Biosciences Inc trading resumes
- Catalyst Biosciences Inc trading halted, volatility trading pause